Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is advancing its proprietary multiple sclerosis therapy candidate, LUCID-MS, into Phase 2 clinical trials following promising Phase 1 results. The company reported that Phase 1 studies in healthy volunteers demonstrated a favorable safety profile and the therapy was generally well tolerated, supporting progression to patient-focused studies. In April 2026, Quantum BioPharma submitted an Investigational New Drug application to the U.S. Food and Drug Administration for LUCID-MS, paving the way for a planned Phase 2 clinical trial in people living with multiple sclerosis.
The therapy is designed to target demyelination and protect or restore myelin integrity, the underlying mechanism of multiple sclerosis. Unlike current treatments that primarily rely on immune modulation, LUCID-MS aims to directly address myelin loss and neurodegeneration, offering a potentially differentiated, first-in-class approach. The company is strengthening operational support for the program through a planned partnership with Allucent and engagement with neurological specialists.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets for neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum BioPharma is focused on the research and development of Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. The company also retains ownership of 19.84% of Unbuzzd Wellness Inc., which markets an OTC version of unbuzzd, and receives royalty payments of 7% of sales until $250 million is reached, then 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products for pharmaceutical and medical uses.
For more information, visit the company's newsroom at https://ibn.fm/QNTM and the full article at https://ibn.fm/AUhNl. Forward-looking statements involve risks and uncertainties as detailed in the company's filings with the SEC, including the Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
